Skip to main content

We've saved some files called cookies on your device. These cookies are:

  • essential for the site to work
  • to help improve our website by collecting and reporting information on how you use it

We would also like to save some cookies to help tailor communications.

BETA
You're viewing an updated version of this service - your feedback will help us to improve it.

Contract Notice

Targeted Prostate Cancer Screening Programme – PSA Laboratory Processing Service

  • First published: 14 October 2026
  • Last modified: 14 October 2026
  • Version: N/A
  •  

  • This file may not be fully accessible.

  •  

Information icon

The buyer is not using this website to administer the notice.

To record your interest or obtain additional information or documents please find instructions within the Full Notice Text. (NOTE: Contract Award Notices and Prior Information Notices do not normally require a response)

Contents

Summary

OCID:
Published by:
NHS England
Authority ID:
AA20005
Publication date:
14 October 2026
Deadline date:
10 November 2026
Notice type:
Contract Notice
Has documents:
No
Has SPD:
No
Has Carbon Reduction Plan:
N/A

Abstract

The Contracting Authority is procuring a targeted prostate cancer screening pathway with a focus on men at increased risk due to an inherited BRCA2 variant utilising the competitive provider selection process under the Health Care Services (Provider Selection Regime) Regulations 2023.<br/><br/>NHS England is seeking a provider to deliver a national Prostate Specific Antigen (PSA) Laboratory Processing and Virtual Screening Pathway Coordination service to support the Targeted Prostate Cancer Screening Programme for England.<br/><br/>The service will include PSA Sample logistics from the agreed collection handoff point, Sample receipt and accessioning, PSA processing and result authorisation, secure result transmission, consumables provision, Sample and pathway tracking, Failsafe management, Programme data and reporting, and Virtual Screening Pathway Coordination. The VSPC function will include coordination of MRI appointments following an above-threshold PSA result and coordination of biopsy/urology appointments following an actionable MRI result, within the Authority-approved pathway and responsibility arrangements.<br/><br/>The procurement does not include delivery of diagnostic MRI scanning or MRI reporting, biopsy procedures, urology treatment, BRCA digital decision-resource development, BRCA genetic testing or development of the national Programme IT system. Clinical delivery and acceptance of onward referrals remain with the relevant commissioned clinical providers.

Full notice text

Contract notice

Section I: Contracting authority

I.1) Name and addresses

NHS England

Wellington House, 133-135 Waterloo Rd

London

SE1 8UG

UK

Contact person: NHS England

E-mail: england.commercialqueries@nhs.net

NUTS: UKI

Internet address(es)

Main address: https://www.england.nhs.uk/

Address of the buyer profile: https://www.england.nhs.uk/

I.3) Communication

The procurement documents are available for unrestricted and full direct access, free of charge at:

https://atamis-1928.my.site.com/s/Welcome


Additional information can be obtained from the abovementioned address


Tenders or requests to participate must be sent electronically to:

https://atamis-1928.my.site.com/s/Welcome


Tenders or requests to participate must be sent to the abovementioned address


Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at:

https://atamis-1928.my.site.com/s/Welcome


I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Targeted Prostate Cancer Screening Programme – PSA Laboratory Processing Service

Reference number: C473446

II.1.2) Main CPV code

85111810

 

II.1.3) Type of contract

Services

II.1.4) Short description

The Contracting Authority is procuring a targeted prostate cancer screening pathway with a focus on men at increased risk due to an inherited BRCA2 variant utilising the competitive provider selection process under the Health Care Services (Provider Selection Regime) Regulations 2023.<br/><br/>NHS England is seeking a provider to deliver a national Prostate Specific Antigen (PSA) Laboratory Processing and Virtual Screening Pathway Coordination service to support the Targeted Prostate Cancer Screening Programme for England.<br/><br/>The service will include PSA Sample logistics from the agreed collection handoff point, Sample receipt and accessioning, PSA processing and result authorisation, secure result transmission, consumables provision, Sample and pathway tracking, Failsafe management, Programme data and reporting, and Virtual Screening Pathway Coordination. The VSPC function will include coordination of MRI appointments following an above-threshold PSA result and coordination of biopsy/urology appointments following an actionable MRI result, within the Authority-approved pathway and responsibility arrangements.<br/><br/>The procurement does not include delivery of diagnostic MRI scanning or MRI reporting, biopsy procedures, urology treatment, BRCA digital decision-resource development, BRCA genetic testing or development of the national Programme IT system. Clinical delivery and acceptance of onward referrals remain with the relevant commissioned clinical providers.

II.1.5) Estimated total value

Value excluding VAT: 238 607.90  GBP

II.1.6) Information about lots

This contract is divided into lots: No

II.2) Description

II.2.2) Additional CPV code(s)

85145000

II.2.3) Place of performance

NUTS code:

UK

II.2.4) Description of the procurement

As part of this process, the Contracting Authority would like to invite interested parties to read and complete our Invitation to Tender within our e-Tendering System Atamis, https://atamis-1928.my.site.com/s/Welcome. This service will be competed under The Health Care Services (Provider Selection Regime) Regulations 2023 and will not be competed via Public Contract Regulations 2015 or via the Procurement Act 2023.<br/><br/>The Contracting Authority will be using Atamis, the Contracting Authority’s e-Tendering system for this procurement exercise. For further information, the ITT documentation can be found via the 'Live Opportunities' list on the e-tendering system.<br/><br/>Only Tenders which pass the applicable compliance checks and all applicable Pass/Fail requirements in Questionnaire 1 – the Basic Selection Criteria Questionnaire in accordance with Document 1 – ITT Instructions, will proceed to Stage 2 evaluation.<br/><br/>Stage 1 (Compliance and Basic Selection Criteria Questionnaire)<br/>Compliance checks will be completed to ensure tenders are completed as per the ITT instructions. The Basic Selection Criteria Questionnaire will evaluate the Basic Selection Criteria. The questions will be evaluated on a Pass/Fail or for information only basis and can be found in Document 3.<br/><br/>Stage 2 (Quality, Social Value and Commercial Envelope)<br/>This will be the evaluation of the Quality and Commercial envelope which contains the Key Criteria questions and can be found in Document 4 (Quality and Social Value Envelope) and Document 5 (Commercial Envelope). Scores from Stage 2 evaluation will form 100% of the final score.<br/><br/>The Key Criteria (as outlined in PSR Regulation 5) for Stage 2 will be evaluated as outlined below:<br/><br/>Stage 2 - Quality & Social Value Envelope - 80%<br/><br/>1. Service model, accountability and pathway operation - 10%<br/><br/>National delivery model, governance, roles/responsibilities, handoffs, escalation and VSPC accountability.<br/><br/>2. Collection packs, sample-taking site interface and logistics - 12% <br/><br/>Consumables, site onboarding, Sample handoff, transport, chain of custody, logistics resilience and exceptions.<br/><br/>3. Laboratory capability, assay control, accreditation and analytical quality - 16%<br/><br/>Laboratory capability, UKAS/ISO 15189, approved PSA assay, IQC/EQA, calibration, validation and analytical consistency.<br/><br/>4. Result reporting, National IT interface, data and management information- 10%<br/><br/>Result transmission, interfaces, acknowledgements, data quality, reconciliation, downtime, MI and reporting.<br/><br/>5. Failsafe, invalid Samples, repeat collection and onward MRI/biopsy coordination - 14%<br/><br/>Failsafe, failed/invalid Samples, repeats, MRI coordination, biopsy/urology handoff, acknowledgement and escalation.<br/><br/>6. Mobilisation, capacity, resilience and business continuity - 8%<br/><br/>Mobilisation, readiness, capacity, testing, resilience, BCP, recovery, transition and exit.<br/><br/>7. Social Value – fair work, sustainable delivery and additional equitable-access benefits – 10%<br/><br/>PSR Key Criteria<br/><br/>In accordance with Regulation 5 of the Health Care Services (Provider Selection Regime) Regulations 2023, the award criteria collectively assess all five PSR Key Criteria as follows:<br/><br/>Quality and Innovation – assessed through Questions 1–6 of the Quality Envelope, including service quality, logistics, laboratory capability, analytical quality, digital/result reporting, Failsafe arrangements, mobilisation, capacity and resilience.<br/><br/>Value – assessed through the Commercial Envelope, weighted at 20%.<br/><br/>Integration, Collaboration and Service Sustainability – assessed principally through Questions 1, 4, 5 and 6, including governance, pathway interfaces, National IT integration, handoffs, onward coordination, capacity, resilience and business continuity.<br/><br/>Improving Access, Reducing Health Inequalities and Facilitating Choice – assessed principally through Questions 2, 5 and 7, including equitable national logistics and access, remote-area arrangements, Failsafe/pathway coordination and additional equitable-access commitments.<br/><br/>Social Value – assessed through Question 7, weighted at 10%.<br/><br/>Stage 2 - Commercial Envelope - 20%<br/><br/>This is a Provider Selection Regime (PSR) Contract Notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 or Procurement Act 2023 do not apply to this award.

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: 238 607.90  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 26

This contract is subject to renewal: No

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section III: Legal, economic, financial and technical information

III.1) Conditions for participation

III.1.1) Suitability to pursue the professional activity, including requirements relating to enrolment on professional or trade registers

List and brief description of conditions:

Applicants will be assessed in accordance with the Health Care Services (Provider Selection Regime) Regulations 2023 on the basis of the information provided in response to the Basic Selection Criteria Questionnaire (assessment Stage 1).

III.1.2) Economic and financial standing

List and brief description of selection criteria:

Selection criteria as stated in the procurement documents.


III.1.3) Technical and professional ability

List and brief description of selection criteria:

Selection criteria as stated in the procurement documents.


III.2) Conditions related to the contract

Section IV: Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

IV.1.8) Information about Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

IV.2) Administrative information

IV.2.1) Previous publication concerning this procedure

Notice number in the OJ S:

2026/S 000-074308

IV.2.2) Time limit for receipt of tenders or requests to participate

Date: 10/11/2026

Local time: 12:00

IV.2.4) Languages in which tenders or requests to participate may be submitted

EN

IV.2.6) Minimum time frame during which the tenderer must maintain the tender

Tender must be valid until: 01/03/2027

IV.2.7) Conditions for opening of tenders

Date: 13/10/2026

Local time: 12:00

Section VI: Complementary information

VI.1) Information about recurrence

This is a recurrent procurement: No

VI.3) Additional information

This is a Provider Selection Regime (PSR) Contract Notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 or Procurement Act 2023 do not apply to this award.

VI.4) Procedures for review

VI.4.1) Review body

Independent patient choice and procurement panel

Wellington House

London

SE1 8UG

UK

VI.5) Date of dispatch of this notice

13/10/2026

Coding

Commodity categories

ID Title Parent category
85111810 Blood analysis services Hospital services
85145000 Services provided by medical laboratories Miscellaneous health services

Delivery locations

ID Description
100 UK - All

Alert region restrictions

The buyer has restricted the alert for this notice to suppliers based in the following regions.

ID Description
There are no alert restrictions for this notice.

About the buyer

Main contact:
england.commercialqueries@nhs.net
Admin contact:
N/a
Technical contact:
N/a
Other contact:
N/a

Further information

Date Details
No further information has been uploaded.

0800 222 9004

Lines are open 8:30am to 5pm Monday to Friday.

Rydym yn croesawu galwadau'n Gymraeg.

We welcome calls in Welsh.